Top Markets
Coin of the day
Tvardi Therapeutics, Inc. Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRD
Rang in aandelen #30251
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages... Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Aandeelprijs
$1.88
Laatst gesynchroniseerd: 2026-08-18
Marktkapitalisatie
$17.59M
Verandering (1 dag)
0.81%
Verandering (1 jaar)
-92.40%
Land
US
Handel Tvardi Therapeutics, Inc. (TVRD)

Categorie

Dividendrendementgeschiedenis voor Tvardi Therapeutics, Inc. (TVRD)
Het dividendrendement (TTM) van Tvardi Therapeutics, Inc. (aandelsymbool: TVRD) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Tvardi Therapeutics, Inc. (TVRD) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.48%
BE